# Ziconotide

> Ziconotide is a synthetic version of a peptide toxin originally isolated from the venom of the marine cone snail Conus magus. It is approved as a prescription analgesic for severe chronic pain in patients who have not responded adequately to other treatments, including systemic opioids. Unlike opioid-based pain medications, it is not an opioid and carries no risk of respiratory depression or opioid-type dependence. It is administered exclusively by continuous intrathecal infusion under specialist supervision, typically via an implanted programmable pump. Because of its narrow therapeutic window and serious psychiatric and neurological risks, its use is restricted to specialized pain management centers.

- URL: https://www.lifeconverted.com/peptides/ziconotide
- Also known as: Prialt, SNX-111, Omega-conotoxin MVIIA
- Primary category: Other & Clinical
- Effectiveness rank: #15 in Other & Clinical
- Evidence level: Well studied
- Route: Intravenous (Approved clinical administration is by continuous intrathecal infusion via an implanted pump; it must never be given intravenously, intramuscularly, or epidurally.)
- Dose range: 2.4-21.6 mcg
- Dose tiers: low 2.4 mcg; moderate 9.6 mcg; high 21.6 mcg
- Half-life: Approximately 4.6 hours in cerebrospinal fluid following intrathecal infusion
- Timing: As directed by your clinician
- Cycle: Continuous intrathecal infusion with no defined on-cycle; dose adjustments are made gradually over weeks on, Not cycled off; discontinuation requires slow downward titration to avoid rebound pain, not abrupt stopping off (Titration is slow and conservative, typically no more than 2.4 mcg/day increases up to twice weekly, to minimize psychiatric and neurological side effects.)
- Storage: Refrigerate unopened vials at 2-8°C, protected from light; do not freeze. Once loaded into an infusion pump reservoir, follow the pump manufacturer's in-use stability guidance.

## Mechanism of action

Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) located on the presynaptic terminals of primary nociceptive afferent neurons in the dorsal horn of the spinal cord. By blocking calcium influx, it inhibits the release of pain-signaling neurotransmitters such as substance P and glutamate, interrupting pain transmission at the spinal level. This action is independent of opioid receptors, which is why it does not produce tolerance or physical dependence in the way opioids do.

## Reported benefits

- Provides an opioid-free option for severe, treatment-refractory chronic pain
- Does not appear to cause tolerance or physical dependence with continued use
- Acts locally at the spinal cord, limiting some systemic side effects seen with oral analgesics
- Can be titrated and adjusted via a programmable intrathecal pump

## Reported side effects

- Significant risk of psychiatric symptoms, including hallucinations, confusion, and mood changes
- Cognitive impairment and memory problems
- Dizziness, nausea, and gait disturbance
- Elevated creatine kinase levels
- Requires an implanted intrathecal pump, carrying procedural and device-related risks

## Common protocols

- Continuous intrathecal infusion via implanted pump for severe chronic pain in patients intolerant of or unresponsive to systemic analgesics, including opioids

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer